Skip to main content
. Author manuscript; available in PMC: 2016 Aug 1.
Published in final edited form as: J Mol Cell Cardiol. 2015 Jun 10;85:215–225. doi: 10.1016/j.yjmcc.2015.06.003

Figure 6. Sfrp2 activates non-canonical Wnt/PCP pathway by inhibiting canonical Wnt6.

Figure 6

(A) Western blot protein analysis of p-JNK in CPCs after overnight treatment with 10 μM C59 Porcupine inhibitor with or without 10 nM Sfrp2.

(B) p-JNK activation in CPCs as assessed by ELISA in the presence or absence of 10 μM C59 Porcupine inhibitor with and without 10 nM Sfrp2 treatment. *P<0.05 compared to Nt; n=6.

(C) p-JNK activation in Control (MSCV-eGFP), constitutively active β-Catenin (MSCV-ΔGSKβCatenin) or dominate negative β-Catenin (MSCV-Axin1) CPCs as assessed by ELISA with and without 10 nM Sfrp2.

(D) p-JNK activation in shControl and shWnt6 CPCs assessed by ELISA in the presence or absence of 10 nM Sfrp2. *P<0.05; n=4. Nt: no treatment.